{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Omaveloxolone+Capsules%2C+10+mg",
    "query": {
      "intervention": "Omaveloxolone Capsules, 10 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T22:27:25.262Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02255422",
      "title": "RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MItochondrial Myopathies"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone capsules, 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 5 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 20 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 40 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 80 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 160 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 53,
      "start_date": "2015-05-05",
      "completion_date": "2017-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-09-29T22:27:25.262Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Akron, Ohio + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02255422"
    },
    {
      "nct_id": "NCT02259231",
      "title": "RTA 408 Capsules in Patients With Melanoma - REVEAL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Unresectable (Stage III) Melanoma",
        "Metastatic (Stage IV) Melanoma"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone Capsules (2.5 mg/capsule)",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab (3 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab (240 mg)",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules (10 mg/capsule)",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules (50 mg/capsule)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2014-10-31",
      "completion_date": "2018-07-23",
      "has_results": true,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-09-29T22:27:25.262Z",
      "location_count": 10,
      "location_summary": "Mobile, Alabama • Fayetteville, Arkansas • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02259231"
    },
    {
      "nct_id": "NCT02255435",
      "title": "A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Friedreich Ataxia"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone Capsules, 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules, 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules, 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules, 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules, 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules, 80 mg",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules, 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules, 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "16 Years to 40 Years"
      },
      "enrollment_count": 172,
      "start_date": "2015-01-31",
      "completion_date": "2025-12-19",
      "has_results": true,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-29T22:27:25.262Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02255435"
    },
    {
      "nct_id": "NCT04008186",
      "title": "A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Subjects"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone",
          "type": "DRUG"
        },
        {
          "name": "Midazolam oral solution",
          "type": "DRUG"
        },
        {
          "name": "Repaglinide 1 MG",
          "type": "DRUG"
        },
        {
          "name": "MetFORMIN 500 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Digoxin tablet",
          "type": "DRUG"
        },
        {
          "name": "Gemfibrozil Tablets",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole capsule",
          "type": "DRUG"
        },
        {
          "name": "Verapamil Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 61,
      "start_date": "2019-06-14",
      "completion_date": "2019-08-28",
      "has_results": false,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-09-29T22:27:25.262Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04008186"
    },
    {
      "nct_id": "NCT03902002",
      "title": "A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone 50 mg capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2019-07-19",
      "completion_date": "2020-01-27",
      "has_results": false,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-09-29T22:27:25.262Z",
      "location_count": 3,
      "location_summary": "Tustin, California • Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03902002"
    },
    {
      "nct_id": "NCT03931590",
      "title": "A Human AME Study for Omaveloxolone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Male Subjects"
      ],
      "interventions": [
        {
          "name": "[14C]-Omaveloxolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2019-04-11",
      "completion_date": "2019-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-09-29T22:27:25.262Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03931590"
    },
    {
      "nct_id": "NCT02029729",
      "title": "RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic or Incurable Non-small Cell Lung Cancer",
        "Relapsed, Refractory Melanoma"
      ],
      "interventions": [
        {
          "name": "omaveloxolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2013-12-31",
      "completion_date": "2015-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-09-29T22:27:25.262Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02029729"
    }
  ]
}